Literature DB >> 33602983

The role of long intergenic non-coding RNA for kinase activation (LINK-A) as an oncogene in non-small cell lung carcinoma.

Parichehr Maleki1, Seyed Javad Mowla2, Mohammad Taheri3,4, Soudeh Ghafouri-Fard5,4, Jamshid Raheb6.   

Abstract

The oncogenic role of long intergenic non-coding RNA for kinase activation (LINK-A) has been appraised in triple-negative breast cancer. However, the molecular function of LINK-A is still unclear in most cancers including lung cancer. The present study aimed to evaluate the impact of down-regulation of LINK-A in A549 and Calu-3 cell lines as cellular models of non-small cell lung carcinoma (NSCLC). We used the RNA interference system to knock down LINK-A. LINK-A expression was significantly reduced by siRNA transfection in A549 and Calu-3 cell lines. LINK-A down-regulation significantly reduced cell viability, colony-forming ability and cell migration, as measured by MTT, colony formation and invasion assays. Finally, cell cycle analysis and Annexin-V/7AAD staining indicated that apoptosis was influenced by LINK-A silencing. Taken together, LINK-A can be proposed as an oncogene in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33602983      PMCID: PMC7892821          DOI: 10.1038/s41598-021-82892-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  45 in total

1.  ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway.

Authors:  Xiaoming Zhu; Xiaobin Guo; Sen Wu; Li Wei
Journal:  Lung       Date:  2016-05-11       Impact factor: 2.584

Review 2.  Long intergenic noncoding RNAs: new links in cancer progression.

Authors:  Miao-Chih Tsai; Robert C Spitale; Howard Y Chang
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

Review 3.  Lung cancer: current therapies and new targeted treatments.

Authors:  Fred R Hirsch; Giorgio V Scagliotti; James L Mulshine; Regina Kwon; Walter J Curran; Yi-Long Wu; Luis Paz-Ares
Journal:  Lancet       Date:  2016-08-27       Impact factor: 79.321

Review 4.  Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

Authors:  Lydia Scarfò; Paolo Ghia
Journal:  Immunol Lett       Date:  2013-10-01       Impact factor: 3.685

5.  Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes.

Authors:  Kazuko Miyazaki; Takeshi Kawamoto; Keiji Tanimoto; Masahiko Nishiyama; Hiroaki Honda; Yukio Kato
Journal:  J Biol Chem       Date:  2002-09-26       Impact factor: 5.157

Review 6.  Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2012-02-13       Impact factor: 6.208

7.  LINK-A Long Non-Coding RNA (lncRNA) Participates in Metastasis of Ovarian Carcinoma and Upregulates Hypoxia-Inducible Factor 1 (HIF1α).

Authors:  Huijun Zhang; Bin Yao; Shengchun Tang; Ying Chen
Journal:  Med Sci Monit       Date:  2019-03-26

8.  LINK-A lncRNA is upregulated in metastatic non-small cell lung cancer and is associated with poor prognosis.

Authors:  Junqiang Liu; Weian Song; Jun Li; Xuechang Li; Rongrong Zhao; Taiqian Gong
Journal:  Oncol Lett       Date:  2019-07-15       Impact factor: 2.967

9.  Combination of peripheral blood mononuclear cell miR-19b-5p, miR- 221, miR-25-5p, and hypertension correlates with an increased heart failure risk in coronary heart disease patients.

Authors:  Yuan Yao; Tao Song; Gang Xiong; Zhaogui Wu; Qi Li; Hao Xia; Xuejun Jiang
Journal:  Anatol J Cardiol       Date:  2018-08       Impact factor: 1.596

10.  BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion.

Authors:  Aarti Sethuraman; Martin Brown; Raya Krutilina; Zhao-Hui Wu; Tiffany N Seagroves; Lawrence M Pfeffer; Meiyun Fan
Journal:  Breast Cancer Res       Date:  2018-10-01       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.